Clinical Trial Update: Study Evaluating EKB-569 in Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating EKB-569 in advanced colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• EKB-569 (EKB-569)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Colorectal Neoplasms, Colonic Neoplasms | Phase 2 | Status: COMPLETED